33 Recruiting Studies Using Glofitamab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Glofitamab
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
📍 UC San Diego Moores Cancer Center — La Jolla, California
Lymphoma
View Study & Checklist ➔A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Diffuse Large B-cell Lymphoma
View Study & Checklist ➔Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma
📍 Beth Israel Deaconess Medical Center — Boston, Massachusetts
Follicular Lymphoma
View Study & Checklist ➔An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
📍 Alaska Oncology & Hematology, LLC — Anchorage, Alaska
Large B-Cell Lymphoma
View Study & Checklist ➔A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
📍 University of California San Francisco - Fresno Center for Medical Education and Research — Clovis, California
B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Aggressive Non-Hodgkin Lymphoma
View Study & Checklist ➔A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
📍 University of Michigan — Ann Arbor, Michigan
Non-Hodgkin's Lymphoma
View Study & Checklist ➔Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
📍 BCCA - Vancouver — Vancouver, British Columbia
Lymphoma, B-Cell
View Study & Checklist ➔A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
📍 City of Hope Medical Center — Pasadena, California
Lymphoma, Non-Hodgkin
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Lymphoma
View Study & Checklist ➔A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
📍 Dana Farber Cancer Institute (Data Collection and Specimen Analysis) — Boston, Massachusetts
Mantle Cell Lymphoma
View Study & Checklist ➔Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics
📍 Icahn School of Medicine at Mount Sinai — New York, New York
Relapsed/Refractory Diffuse Large B-cell Lymphoma
View Study & Checklist ➔GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
📍 Massachusetts General Hospital — Boston, Massachusetts
Lymphoma
View Study & Checklist ➔TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
📍 Rhode Island Hospital — Providence, Rhode Island
Diffuse Large B Cell Lymphoma
View Study & Checklist ➔Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
📍 Princess Margaret Cancer Centre — Toronto, Ontario
Diffuse Large B Cell Lymphoma (DLBCL)
View Study & Checklist ➔CAR-T Followed by Bispecific Antibodies
📍 University of Nebraska Medical Center — Omaha, Nebraska
Large B-cell Lymphoma
View Study & Checklist ➔A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
📍 Mayo Clinic in Arizona - Phoenix — Phoenix, Arizona
Relapsed/Refractory Non-Hodgkin Lymphoma
View Study & Checklist ➔Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
📍 University of California, Davis — Davis, California
Mantle Cell Lymphoma
View Study & Checklist ➔Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Blastoid Variant Mantle Cell Lymphoma
View Study & Checklist ➔A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
📍 Alta Bates Summit Medical Center — Berkeley, California
Lymphoma
View Study & Checklist ➔Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Recurrent Mantle Cell Lymphoma
View Study & Checklist ➔A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
📍 MD Anderson Cancer Center — Houston, Texas
B Cell Lymphoma
View Study & Checklist ➔Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
📍 City of Hope Medical Center — Duarte, California
Mantle Cell Lymphoma
View Study & Checklist ➔A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
📍 Children's Hospital of Alabama — Birmingham, Alabama
Mature B-Cell Non-Hodgkin Lymphoma
View Study & Checklist ➔Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial
📍 OHSU Knight Cancer Institute — Portland, Oregon
Mantle Cell Lymphoma
View Study & Checklist ➔External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
📍 Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Diffuse Large B Cell Lymphoma
View Study & Checklist ➔A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
📍 Mayo Clinic Phoenix — Phoenix, Arizona
B-cell Malignancy
View Study & Checklist ➔A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Diffuse Large B Cell Lymphoma (DLBCL)
View Study & Checklist ➔Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
📍 Winship Cancer Institute at Emory University — Atlanta, Georgia
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
📍 Clinical Trial Site — New Haven, Connecticut
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
View Study & Checklist ➔A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
📍 University of Miami Sylvester Cancer Center — Miami, Florida
Lymphoma
View Study & Checklist ➔Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
📍 MD Anderson Cancer Center — Houston, Texas
Phase 2 Study
View Study & Checklist ➔A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
📍 Alaska Oncology & Hematology, LLC — Anchorage, Alaska
B-Cell Non-Hodgkins Lymphoma
View Study & Checklist ➔